



ASX Release

14 October 2021

NOTIFICATION OF EXPIRY OF UNLISTED OPTIONS

Zelira Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) advises that the attached letter has been sent to holders of ZLD Unlisted Options exercisable at \$0.03125 on or before 17 November 2021, as notification of the expiry of their options on 17 November 2021.

Tim Slate
Company Secretary

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

- ENDS -

For further information please contact:

Company

Dr Oludare Odumosu
Managing Director & CEO
+1 909 855 0675
oodumosu@zeliratx.com

Investors

Market Eye Pty Ltd
ABN 54 137 305 527
Melbourne | Sydney
T: +61 3 9591 8900
F: +61 3 9591 8999
W: www.marketeye.com.au



About Zelira Therapeutics (www.zeliratx.com)

Australia

Level 3
101 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

USA

5110 Campus Drive
Suite 150
Plymouth Meeting, PA
19462
UNITED STATES OF AMERICA
Tel: +1 484-630-0650

Zelira Therapeutics Ltd (**ASX:ZLD, OTCQB:ZLDAF**) is a leading global biopharmaceutical company manufacturing and marketing cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access to the world's largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Australia, Pennsylvania, Louisiana and Washington D.C. with other states in the US expected to follow. Zelira is also generating revenue in Australia from its proprietary and patented Zenivol™ - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol™ has successfully completed the first Phase 1b clinical trial for chronic insomnia where it was found to be a safe and effective treatment. This clinical trial is published in the prestigious journal 'Sleep'. In 2020, Zelira partnered with SprinJene®Natural to develop and commercialise natural and organic oral care products under the SprinJeneCBD brand, as part of Zelira's OTC business. The SprinJeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company conducts its work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States



ACN 103 782 378

14 October 2021

Dear Option Holder

Your unlisted Zelira Therapeutics options are due to expire on 17 November 2021

At the date of this notice, you are the registered holder of unlisted options in Zelira Therapeutics Limited (Zelira) with an exercise price of 3.125 cents. These options will expire unless they are exercised on or before that date. It is therefore important that you carefully read the following information and, if necessary, seek independent financial advice before deciding what action to take.

Actions you can take

The courses of action available to you as a holder of options, are to:

1. Exercise your options before 5.00pm (AWST) on 17 November 2021; or
2. Do nothing (ie. allow them to expire).

There is no obligation to exercise your options. However, if you do not exercise your options, they will expire at 5.00pm (AWST) and your right to subscribe for fully paid ordinary shares in Zelira at 3.125 cents per share will lapse.

Number of options held & the amount due on exercise

The number of options held at the date of this notice and the amount due on any exercise of options is shown on the accompanying form entitled "Application Form on Exercise of Unlisted Options"

The exercise price of the options is 3.125 cents per option. You may exercise your options in full or in part. One fully paid ordinary share in Zelira will be issued for each option exercised.

In order to exercise your options, you must pay the full amount due on exercise by bank transfer or cheque. More information about payment is set out on the accompanying form. **We encourage payment via bank transfer if possible**

Share price information

The closing price of fully paid ordinary shares in Zelira (ASX: ZLD) on ASX on Wednesday, 13 October 2021, being the last trading date prior to this notice, was 3.8 cents.

The highest price at which the fully paid ordinary shares in Zelira have traded on ASX in the last three months preceding the date of this notice was 4.9 cents on 21 July 2021. The lowest price at which fully paid ordinary shares traded in Zelira on the ASX in the three months preceding the date of this notice was 3.5 cents on 1 and 2 September 2021.

Exercising your options

To exercise your options, please follow the instructions on the accompanying "Application Form on Exercise of Unlisted Options" form. You must return the completed form to Zelira's share registry, Computershare Pty Limited, together with payment of the full exercise price for the number of options you wish to exercise.

The completed form and payment of the exercise price must be received by Zelira's share registry no later than 5.00pm (AWST) on 17 November 2021. If you intend to exercise your options, we recommend that your completed form and your payment for the exercise price are received by the share registry by no later than 5.00pm (AWST) Tuesday, 16 November 2021.

If you have any questions about exercising your options, please contact Zelira by telephone on (08) 6558 0886 or by email at enquiries@zeliratx.com.

Yours sincerely

Tim Slate
Company Secretary